Results 111 to 120 of about 6,234 (145)

A Comprehensive Review of Thoracic Aortic Disease in Immunosuppressed States: Clinical Signals, Mechanisms, and Implications for Surveillance. [PDF]

J Cardiovasc Dev Dis
Srivastava Y, Hershenhouse K, Faith I, Nelson T, Ferrell BE, Alberto AJ, Sugiura T.   +6 more
europepmc   +1 more source

5-Fluorouracil-Related Lactic Acidosis in a Patient with Colon Cancer. [PDF]

Intern Med
Osawa Y, Kazaoka M, Akita T, Nemoto D, Ohtake T.   +4 more
europepmc   +1 more source

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Chiddarwar T, Blaes A, Kuntz K.
europepmc   +1 more source

Formulation and Physicochemical Characterization of Capecitabine-Loaded Cubosomes for Enhanced Drug Delivery System. [PDF]

Drug Des Devel Ther
Salawi A.
europepmc   +1 more source

Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver. [PDF]

J Investig Med High Impact Case Rep
Hatipoglu D, Jamali A, Sheng E, Reddy KR.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota

Toxicology, 2021
The incidence and mortality of cancer are rapidly growing all over the world. Nowadays, antineoplastic antimetabolites still play a key role in the chemotherapy of cancer. However, the interindividual variations in the efficacy and toxicity of antineoplastic antimetabolites are nonnegligible challenges to their clinical applications.
Xinyi Huang, Lulu Chen, Zhenyu Li, Binjie Zheng, Na Liu, Qing Fang, Jinsheng Jiang, Tai Rao, Dongsheng Ouyang   +8 more
openaire   +2 more sources

Nelarabine: A novel purine antimetabolite antineoplastic agent

Clinical Therapeutics, 2007
Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.This article reviews the pharmacology, mechanism of action, and ...
Larry W, Buie, Stacy S, Epstein, Celeste M, Lindley   +2 more
openaire   +2 more sources

Intercalator-induced, toposiomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites

International Journal of Radiation Oncology*Biology*Physics, 1986
Defining specific biochemical targets of active antineoplastic agents could aid in discovering better anticancer therapy and more thoroughly understanding the biochemical basis of malignancy. Through a series of cellular and biochemical studies, we and others have identified the nuclear enzyme topoisomerase II as the target of several active agents ...
L A, Zwelling, L, Silberman, E, Estey
openaire   +2 more sources

Glycolysis-dependent antimetabolites: Possible improvement in antineoplastic selectivity

Medical Hypotheses, 1979
The increased rate of glycolysis in neoplastic cells may be used to design tentatively antimetabolites whose detoxification would be faster in normal cells. Pyruvo-substituted nucleotides are examined in this respect and their expected differential metabolism outlined.
openaire   +2 more sources